Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3... | June 5, 2023

Related Keywords

,Tanuja Chitnis ,Howardl Weiner ,Gabriele Cerrone ,Irina Koffler ,Tarun Singhal ,Paul Spencer ,Howard Weiner ,Lifesci Advisors ,Eu Press ,Ann Romney Center ,Imaging Program In Neurologic Diseases ,Tiziana Life Sciences ,Tiziana Life Sciences Ltd ,Nasdaq ,Business Development ,Harvard Medical School ,Expanded Access ,Advisory Board ,Romney Center ,Neurologic Diseases ,Life Sciences ,Positron Emission Tomography ,General Brigham Healthcare System ,Assistant Professor ,Medical School ,Principal Investigator ,Executive Chairman ,Chief Executive Officer ,Investor Relations ,Sci Advisors ,Tiziana Life Sciences Ltd Stock Exchange ,News ,Information ,Press Release ,Results ,Confirm ,Positive ,Signal ,Reviously ,Eported ,N ,The ,First ,Two ,Xpanded ,Access ,Patients ,Who ,Moth ,Subsequently ,Remonstrated ,Linical ,Mprovementsphase ,A ,Trial ,Track ,O ,Begin ,N Tlsa Bmg889121031 ,